The Genetic Landscape of Cardiomyopathy and Its Role in Heart Failure  by McNally, Elizabeth M. et al.
Cell Metabolism
PerspectiveThe Genetic Landscape of Cardiomyopathy
and Its Role in Heart FailureElizabeth M. McNally,1,* David Y. Barefield,1 and Megan J. Puckelwartz1
1Center for Genetic Medicine, Northwestern University, Chicago, IL 60611, USA
*Correspondence: elizabeth.mcnally@northwestern.edu
http://dx.doi.org/10.1016/j.cmet.2015.01.013
Heart failure is highly influenced by heritability, and nearly 100 genes link to familial cardiomyopathy. Despite
themarked genetic diversity that underlies these complex cardiovascular phenotypes, several key genes and
pathways have emerged. Hypertrophic cardiomyopathy is characterized by increased contractility and a
greater energetic cost of cardiac output. Dilated cardiomyopathy is often triggered by mutations that disrupt
the giant protein titin. The energetic consequences of these mutations offer molecular targets and opportu-
nities for new drug development and gene correction therapies.Heart Failure and Cardiomyopathy
The clinical diagnosis of heart failure (HF) arises when cardiac
output is insufficient to supply demand. Acute HF can occur
from abrupt occlusion of a coronary artery, catastrophic valve
dysfunction,malignant hypertension, or other states that provoke
an urgent mismatch between supply and demand. Chronic HF is
experienced as a slow decline in function, measured over years,
as fatigue, breathlessness, and often evidence of end organ
vascular insufficiency. Fluid overload and arrhythmias contribute
to the HF spectrum. The timeline of chronic HF is punctuated by
acuteHFexacerbations, and theannual costs associatedwithHF
exceed $30 billion U.S. dollars (Heidenreich et al., 2013). Thema-
jor costs are calculated in repeated hospitalizations, the need for
medical and device intervention, and lost productivity (Dunlay
et al., 2011). Because of the chronic and progressive nature of
HF, there is opportunity to intervene at early stages.
HF is frequently accompanied by cardiomyopathy, defined as
a morphologically abnormal heart. In vivo, echocardiography
provides critical information regarding chamber dimensions
and function, while magnetic resonance imaging also provides
a more in-depth visualization of myocardial tissue composition
(Mahrholdt et al., 2005; Rickers et al., 2005). The major forms
of cardiomyopathy include hypertrophic, dilated, restrictive,
and arrhythmogenic (sometimes referred to as right ventricular)
cardiomyopathy (Maron et al., 2006). Each of these forms of car-
diomyopathy has a major heritable component, and genetic
testing is now used in the evaluation of individuals with cardio-
myopathy (Arndt and MacRae, 2014; McNally et al., 2013; Tee-
kakirikul et al., 2013). The genes for which there is genetic testing
are shown in Figure 1. Overall, there are nearly 100 genes linked
to inherited forms of cardiomyopathy. More than 20 genes are
implicated in hypertrophic cardiomyopathy (HCM), while fewer
genes are linked to arrhythmogenic right ventricular cardiomy-
opathy (ARVC). Dilated cardiomyopathy (DCM) is the most
genetically heterogeneous. The same gene may be implicated
in multiple forms of cardiomyopathy, underscoring the impor-
tance of genomic context in the pathophysiology of disease-
associated variants. In addition to genetic causes, ischemia,
toxic insult, and valvular defects contribute to DCM, and more
than one etiologymay contribute to any form of cardiomyopathy.
Despite this heterogeneity, several essential classes of genetic174 Cell Metabolism 21, February 3, 2015 ª2015 Elsevier Inc.mutations are present around which existing and novel therapies
can be applied.
Genetic Assessment in Cardiomyopathy
The large number of genes responsible for cardiomyopathy, as
well as the myriad of diverse mutations within each of these
genes, produces remarkable heterogeneity for this complex dis-
order. Individual cardiomyopathy-associated genetic variants
are infrequent in the general population (<1 in 500), and individual
genetic variants associate with a range of expressivity causing
mild and severe forms of disease. For example, deletion of argi-
nine 14 in phospholamban (PLN gene) was described with early
onset cardiomyopathy and accompanying lethal arrhythmias
(Haghighi et al., 2006). In one population, this same mutation
was found in 12% of ARVC and 15% of DCM subjects (van der
Zwaag et al., 2012), and a follow-up retrospective evaluation of
295 gene mutations carriers confirmed an earlier age of onset
of both arrhythmias and cardiomyopathy (van Rijsingen et al.,
2014). Curiously, this same mutation was described in individ-
uals with late-onset DCMwithout evidence of ventricular arrhyth-
mias (DeWitt et al., 2006). The range of outcome with the same
given variant is consistent with the presence of genetic and
environmental factors that modify outcome (Arad et al., 2002;
Marian, 2000) (Figure 2). Sex is a modifier of cardiomyopathy
expression. Rare truncating mutations in TTN, the gene encod-
ing the giant protein titin, are associated with more severe left
ventricular (LV) dysfunction in males compared to females (Her-
man et al., 2012). Sex differences have also been described in
HCM, where males are usually more affected, and this is recapit-
ulated in animal models (Geisterfer-Lowrance et al., 1996; Vik-
strom et al., 1996). Sex differences are attributed to a number
of factors including hormone levels, gene expression differ-
ences, and basic differences in physiology, including heart
size. Factors other than sex also influence the expression of
genetic variants on the pathophysiology of heart disease.
Secondary or additional genetic variants also contribute
to severity or progression of disease. In individuals with more
than one mutation, there is often earlier onset and in some cases
a more rapid progression of disease (Girolami et al., 2010;
Golbus et al., 2014; Ingles et al., 2005; Richard et al., 1999). A
recent survey used whole-genome sequencing of 11 unrelated
Figure 1. Shown Are the Genes That Have Been Linked to Human
Inherited Cardiomyopathy
Those genes responsible for HCM are in pink, and for DCM in blue. There are a
number of genes that cause both HCM and DCM (purple). Mutations in genes
encoding desmosomal and other proteins cause arrhythmogenic right ven-
tricular cardiomyopathy (ARVC, green), and there is overlap between muta-
tions in these genes that leads to other forms of cardiomyopathy.
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(Golbus et al., 2014). In 9 of 11 individuals, the primary dis-
ease-causing variant was identified, usually because it segre-
gated with disease. However, two cases had additional, rare,
potentially pathogenic variation. Closer inspection of these fam-
ilies revealed that these secondary variants were segregating
with a more severe phenotype, indicating that multiple rare var-
iants may contribute to altered disease course within a family.
Common or higher-frequency variation also impacts the effects
of underlying pathogenic variants. Recent work has revealed
an association between severity of cardiomyopathy and mito-
chondrial DNA haplogroup (Strauss et al., 2013). Human mito-
chondrial DNA can be divided into groups based on shared
genealogy. Strauss and colleagues studied a large Mennonite
family with autosomal recessive myopathy and cardiomyopathy
caused by a frameshift mutation in the gene coding for adenine
nucleotide translocator-1. The authors found considerable vari-
ability in the progression and severity of the cardiac phenotype
that segregated with the maternal lineage. Sequencing showed
segregation of two mitochondrial haplogroups, one of which
conferred more severe cardiomyopathy (Strauss et al., 2013).
These data underscore how the expressivity and penetrance
of specific cardiomyopathy gene variants varies widely (Hersh-
berger et al., 2013). In silico algorithms score pathogenicity on
numeric scales, relying on conservation data and less so on
structural information (Ritchie and Flicek, 2014). Based on segre-
gation with clinical phenotype, more highly penetrant mutations
have been described, but even highly penetrant mutations may
require the context of specific genetic backgrounds or ethnicities
to fully manifest, and this ‘‘background effect’’ has been
modeled in mice (Semsarian et al., 2001; Suzuki et al., 2002;
Wheeler et al., 2009). With the emergence of sequence data
from large numbers of ethnically diverse humans, it has become
clear that ‘‘pathogenic’’ variation is found at a higher than ex-
pected rate. Specifically, previously described pathogenicmuta-
tions are present at a frequency higher than the prevalence of
cardiomyopathy (Andreasen et al., 2013; Golbus et al., 2012;
Pan et al., 2012). Not all genetic variants induce the same degreeof cardiac dysfunction, and for primary mutation and secondary
modifiers there are ‘‘mild’’ and ‘‘severe’’ mutations. Determining
the expressivity of given mutations is challenging, and computa-
tional algorithms, however imperfect, emerging now serve as an
adjunct to interpreting the pathogenicity of cardiomyopathy
mutations. Genetic variation remains a strong predictor of risk
for developing cardiomyopathy, particularly within families
where a primary gene mutation has been identified.
Recent work has focused on reclassifying the potential patho-
genicity of variants based on frequency in the population at large,
with higher-frequency variants considered less pathogenic
(MacArthur et al., 2014). This methodology assumes that patho-
genic alleles will be found in a frequency in the population less
than or equal to the disease prevalence and assumes that indi-
vidual variants are sufficient to cause disease. Studies of pene-
trance and expressivity indicate that the entire genomic context,
as well as the environment, dictate the role of particular variants
(Hershberger et al., 2013). Pathogenicity of particular variants
must be considered within the phenotype context, as many car-
diomyopathic genetic variants are necessary but not sufficient to
cause disease. Most large human genetic data sets include indi-
viduals who have not been specifically evaluated for subtle signs
of cardiomyopathy and/or individuals who are too young to have
yet developed disease. Similarly, it is expected that additional
genetic and environmental stimuli are necessary to express the
full phenotype of cardiomyopathy and HF. In addition to these
secondary genetic and environmental modifiers, epigenetic in-
fluences may markedly alter the expression of mutant alleles or
alternative genetic pathways that diminish or enhance pathoge-
nicity. As sparks do not cause fire in the absence of oxygen,
cardiomyopathy mutations require context to fully manifest. Var-
iants are only pathogenic in a larger context that includes both
the susceptible genetic and environmental conditions (Figure 2).
Exploring and defining the genetic and environment stimuli
necessary for cardiomyopathy expression is critical, as these
modifiers influence outcome and are targets for intervention.
Hypertrophic Cardiomyopathy and Thick Filament Gene
Mutations
HCM is estimated at 1:500 in younger individuals and is enriched
in families. This estimate derives from a population-based survey
of individuals 23–35 years of age (Maron et al., 1995). Given the
broad age range of HCM and the appreciation that some genetic
mutations have later onset, the overall population prevalence is
higher. An Olmstead County study conducted in 1985 identified
a similar prevalence for HCM (19.7 per 100,000) and a higher
prevalence for DCM (36.5 per 100,000). This study and the previ-
ous one rely on older methods of detection, and as such likely
underestimate the prevalence of HCM. Hypertrophy of the ven-
tricular myocardium arises in response to physiological stimuli,
such as exercise, and pathological stimuli such as hypertension
or aortic stenosis. In genetic HCM, autosomal dominant muta-
tions in the MYH7 and MYBPC3 genes account for nearly 80%
of inherited HCM (Kensler et al., 2011). These genes encode the
sarcomere thick filament proteins b-myosin heavy chain (MYH7)
and cardiac myosin binding protein-C (cMyBP-C). Although they
are both highly associated with HCM, the mechanisms of the
HCM-causing mutations in these two genes differ. The majority
of pathogenic variants in MYH7 that cause HCM result in aminoCell Metabolism 21, February 3, 2015 ª2015 Elsevier Inc. 175
Figure 2. Familial Studies for Inherited
Cardiomyopathy Often Demonstrate a
Primary Pathogenic Variant, and
Pathogenic Variants Differ in Their Effect on
Phenotypic Outcome
Each genome contains many additional variants
that serve to modify the expression of the primary
pathogenic variant. These secondary modifers
may be common or rare in the population. In
addition to these genetic modifiers, comorbidities,
environmental factors, and sex modulate the
expression of cardiomyopathy. The manifestation
of cardiomyopathy varies over the lifetime of the
individual. Those mutations, or combinations of
mutations, with the most potent effect on pheno-
type manifest earlier in life. Milder mutations may
not express until later in life or may remain sub-
clinical throughout the lifetime of the individual.
(Dilated, DCM; hypertrophic HCM; arr right ven-
tricular, ARVC.)
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affect function. In contrast, the majority of pathogenic HCM-
causing MYBPC3 variants are premature stop codons or frame-
shifting mutations, frequently resulting in absence of protein.
MYBPC3 variants are thought to have a milder disease course
with later onset then mutations in MYH7 (Charron et al., 1998;
Maron et al., 2001), which may be attributed to the difference in
pathogenic mechanisms between mutations in these genes.
MYH7 encodes b myosin heavy chain (bMHC), the thick fila-
ment protein responsible for hydrolyzing ATP to produce force.
Myosin can be divided into the globular head domain and its
coiled-coil rod domain. The myosin head is attached to an arm
that articulates away from the rod region on a flexible hinge to
extend into the interfilament space (Figure 3). The rod domain
mediates the formation of the thick filament with its character-
istic periodicity (Moore et al., 2012). Mutations in MYH7 have
been identified in all regions of the protein, with more mutations
concentrating in the ATPase domain, actin binding domain, and
domains responsible for force transmission (Walsh et al., 2010).
Although occurring at lower frequency, mutations in the rod
domain have also been linked to HCM (Blair et al., 2002).
Modeling MYH7 mutations has been achieved using materials
from human tissues, in vitro or cell-based expression, or genetic
engineering in mice. Each of these methods has limitations, and
the results from distinct approaches have not always produced
consistent findings. Mice, like other small mammals, express
a-MHC as the major cardiac myosin (encoded byMYH6), rather
than bMHC, like the larger human heart. aMHC, while similar in
overall structure to bMHC, has an intrinsically faster rate of
ATP hydrolysis and contractile kinetics (Korte et al., 2005). The
intrinsic capabilities of a-MHC versus b-MHC can lead to the
same mutation demonstrating different biophysical characteris-
tics (Lowey et al., 2008).176 Cell Metabolism 21, February 3, 2015 ª2015 Elsevier Inc.There are hundreds of distinct
missense MYH7 mutations responsible
for HCM, and a clear unifying hypothesis
has been elusive. Clinically, HCM is often
characterized by a hyperdynamic state in
which there is an increase in LV ejection
fraction from 60% to 70% or more. Forexample, the R453CMYH7 HCM mutation displays an impaired
catalytic cycle of ATP hydrolysis despite few biochemical alter-
ations in the ATPase domain, and this mutation counterintui-
tively results in increased contractility (Bloemink et al., 2014;
Sommese et al., 2013). Increasing evidence suggests that
HCM mutations in MYH7 cause increased energy usage due
to a less efficient myosin motor and that this energetic
mismatch results in perturbed metabolic state (Crilley et al.,
2003). As one indication of this energetic mismatch, reduced
phosphocreatine levels (PCr) have been observed using 31P
NMR spectroscopy of animal models of HCM and materials
from human HCM patients (Ingwall, 2014; Witjas-Paalberends
et al., 2014a, 2014b). Human hearts expressing the MYH7
R403Q mutation generate increased tension and faster actin
sliding velocities, but at a higher energetic cost (Alpert et al.,
2005). Mice engineered with the R403Q HCM-associated muta-
tion had reduced rate of relaxation and increased end diastolic
pressure after inotropic stimulation (Tyska et al., 2000). A similar
decrease in PCr and increased ADP was seen in these hearts,
consistent with a higher energetic cost of contraction (Spindler
et al., 1998).
In addition to MYH7 missense mutations in HCM, MYH7
missense variants are also found in DCM. DCM-associated
MYH7 missense mutations have been modeled in mice, albeit
in the context of Myh6. However, these mutations show an
increased tension cost, with more ATP required for a given
amount of shortening, depressed actin sliding velocities, and
gross dilation (Schmitt et al., 2006). In contrast to the hypercon-
tractile HCM mutations, DCM mutations, when modeled in ex-
pressed myosin, cause a hypocontractile state and quickly
lead to HF (Bloemink et al., 2014; Sommese et al., 2013).
The second major thick filament protein implicated in HCM
is MYBPC3, which encodes cardiac myosin binding protein C
Figure 3. Myosin Heads Protrude from the Thick Filaments, in
Green,to Interact with Actin Containing Thin Filaments, in Yellow
Multiple sites throughout the sarcomere and cardiomyocyte are now the tar-
gets for new drug development for heart failure (red stars). (1) Small molecules
like omecamtiv are aimed at myosin ATPase activity to increase or decrease
contractility. (2) Antisense or RNAi approaches are being tested to silence
mutant alleles, but not normal alleles. (3) cMyBP-C phosphorylation can be
modified through kinase/phosphatases to modulate its ‘‘brake effect’’ on
crossbridge cycling. (4) Calcium handing in the sarcoplasmic reticulum is a
target in development. (5) Palmitoyltransferase-1 can be altered using per-
hexiline to shift metabolic substrate usage from fatty acid oxidation to
glycolysis. (6) The regulation of nitric oxide synthase can be used to change
cellular redox state and prevent glutathionylation and dysregulation of
myofilament proteins.
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frequency in HCM cohorts, each representing approximately
40% of identified mutations. In contrast to MYH7 HCM muta-
tions, which are mainly nonsynonymous single nucleotide poly-
morphisms (nsSNPs), MYBPC3 mutations more commonly
disrupt the reading frame. By disrupting the carboxyl terminus
of cMyBP-C, these mutations alter the myosin and titin binding
sites and disallow mutant cMyBP-C incorporation in the sarco-
mere. cMyBP-C is incorporated into the thick filament through
direct binding of its carboxyl terminus to the myosin rod and
also to the giant protein titin (Freiburg and Gautel, 1996; Gilbert
et al., 1996). cMyBP-C includes eight immunoglobulin (Ig) do-
mains along its length, with three fibronectin (Fn) domains to-
ward its carboxyl terminus. cMyBP-C extends transversely into
the interfilament space where its amino-terminal region interacts
with themyosin S2 region and actin in a phosphorylation-depen-
dent manner (Barefield and Sadayappan, 2010; Bezold et al.,
2013; Kunst et al., 2000). The phosphorylation state of three
serine residues mediates cMyBP-C’s ability to regulate cross-
bridge cycling, and dysregulation of these residues results in car-
diomyopathy (Sadayappan et al., 2005, 2006). Recent work has
clearly defined the role of cMyBP-C as a ‘‘molecular brake’’ on
myosin crossbridge cycling, resulting in slowing of actin sliding
velocities while in a dephosphorylated state (Previs et al.,
2012). However, phosphorylation of cMyBP-C by various up-
stream pathways, notably PKA, reduces the inhibitory effect of
cMyBP-C in a gradedmanner, with phosphorylation of additional
sites providing additional relief of myosin inhibition, allowing
throttling of this effect (Weith et al., 2012a, 2012b). In addition,
it has been recently shown that cMyBP-C’s interaction with actin
displaces a-tropomyosin, thusmodifying thin-filament activation
(Mun et al., 2014).Oxidative modifications, often accompanying pathological
remodeling of the heart, have been reported having detrimental
effects on cMyBP-C and sarcomere function. Using a hyperten-
sive mouse model demonstrating diastolic dysfunction prior to
hypertrophic remodeling, cMyBP-C was determined to be gluta-
thionylated at three cysteine residues (Patel et al., 2013).
This oxidative modification resulted in increased myofilament
calcium sensitivity in isolated myofilaments. Treatment with tet-
rahydrobiopterin prevented cMyBP-C glutathionylation and
improved relaxation kinetics and diastolic dysfunction (Jeong
et al., 2013). While additional work is required to determine
whether these channels arewhollymediated by cMyBP-C oxida-
tion, the possibility of treatment prior to the onset of hypertrophy
with antioxidant agents warrants further investigation.
With these data, it is now clear that cMyBP-C regulates
contractility and alters sarcomere energetics. HCM-associated
MYBPC3 mutations, especially those that reduce the amount
of cMyBP-C, promote a loss of crossbridge cycling inhibition.
The loss of cMyBP-C regulation has been shown to decrease
maximal force development in samples of human tissue from
mutation carriers (van Dijk et al., 2014) and in mouse models of
disease (Barefield et al., 2014; Harris et al., 2002). However,
these MYBPC3 mutations have been shown to increase the en-
ergetic cost of contraction in a manner similar to that of MYH7
mutations (Witjas-Paalberends et al., 2014b). WhetherMYBPC3
mutations act by haploinsufficiency or dominant-negative activ-
ity has been examined, and evidence for truncated cMyBP-C
protein has been lacking (Marston et al., 2009). Thus, MYBPC3
mutations appear to act mainly by reducing protein content
(Barefield et al., 2015; van Dijk et al., 2009). Treatment has there-
fore focused on restoring protein levels through gene therapy,
with some notable recent success in a mouse model (Mearini
et al., 2014).
In South Asian populations, it is estimated that 4% of the pop-
ulation carries a 25 bp deletion in intron 32 ofMYBPC3 (Dhanda-
pany et al., 2009). This variant increases the risk for HF and
cardiomyopathy. This deletion induces skipping of the down-
stream exon near the 30 end of MYBPC3. The true prevalence
throughout South Asia has been estimated to be lower, but larger
population samples are likely needed (Simonson et al., 2010).
This deletion has also been linked to increased LV dysfunction
after myocardial infarction (Srivastava et al., 2011), consistent
with this variant increasing susceptibility to HF, especially in
combination with other cardiac insults. Rare instances of individ-
uals with two mutant alleles of MYBPC3 and early onset lethal
disease have been described and often associate with the
feature of noncompaction (Dellefave et al., 2009; Lekanne Dep-
rez et al., 2006; Schaefer et al., 2014;Wessels et al., 2014). There
is an emerging view that HCM can be subdivided into ‘‘sarco-
mere’’ versus ‘‘nonsarcomere,’’ and that pathophysiology and
outcome are different between these groups (Olivotto et al.,
2008, 2011).
The Thin Filament
Crossbridge formation between myosin heads and actin fila-
ments is largely regulated by the proteins of the thin filament.
The thin filament is composed of actin, tropomyosin, the
troponin complex including troponin T (the tropomyosin binding
subunit), troponin I (the inhibitory subunit), and troponin C (theCell Metabolism 21, February 3, 2015 ª2015 Elsevier Inc. 177
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also contribute to this regulation. Regulation of crossbridge
formation depends on the Ca2+ and ATP availability and the
conformation of the troponin-tropomyosin complex on the actin
filament (Lehman et al., 2000). The complex exists in three
states, each of which determines the extent of actin and myosin
interaction (McKillop and Geeves, 1993). HCM-causing muta-
tions have been identified in each of these components, and
the possibility that these proteins exert their effect through
changing sarcomere energetics and the cost of contraction
has been suggested (Tardiff, 2011).
Recently, Moore and colleagues examined the tropomyosin-
binding region of cardiac troponin T, a region that harbors severe
and phenotypically diverse HCM mutations (Moore et al., 2014).
In vitro motility assays showed that specific mutations in cardiac
troponin T disrupted weak electrostatic interactions between the
thin filament and myosin. Complementary in vivo data indicate
that these same mutations cause cardiac remodeling and
disarray of the myofiber, suggesting that the weak crossbridge
formation causes destabilization of the myofilament structure,
ultimately resulting in disease (Moore et al., 2014).
Titin, the Third Filament, a Gene for DCM
The giant protein titin is necessary for the passive forces that
maintain sarcomere integrity, and these passive forces play a
critical role in LV mechanics, especially filling during diastole.
Titin is the largest known protein and spans half the sarcomere
from Z-disk to M-line (Fu¨rst et al., 1988). Adjacent to the M-line
titin contains a titin kinase domain (TK) (Gautel, 2011). The
A-band portion of titin is composed of both Ig and fibronectin
domains (Labeit et al., 1992). The I-band portion is composed
of two ‘‘spring-like’’ domains in cardiac muscle: the N2B, and
PEVK along with tandem immunoglobulin (Ig) segment. These
‘‘spring-like’’ domains are responsible for passive force during
sarcomere stretch (reviewed in Anderson and Granzier, 2012).
Several mouse models have been created to dissect titin’s
role in the sarcomere. Lee and colleagues deleted the region of
TTN encoding its N2B region and found that passive tension
was elevated, triggering an increase in calcium sensitivity at
long sarcomere length (Lee et al., 2010). Increases in calcium
sensitivity result in increased length-dependent activation, indi-
cating that passive tension induced by titin is a factor in the
Frank-Starling mechanism of the heart (Katz, 2002). In further
support of the idea that increased titin-induced passive tension
results in increased length-dependent activation, N2B-deleted
mice have higher LV diastolic stiffness and diastolic dysfunction
(Lee et al., 2010). Truncation of the PEVK region, another spring-
like element, also exhibited increased passive tension along with
diastolic dysfunction (Granzier et al., 2009). A mouse lacking the
tandem Ig segment showed similar physiology (Chung et al.,
2013). Disrupting the I-band/A-band junction of titin also
increased strain of the spring regions of the I-band and caused
diastolic dysfunction in themice (Granzier et al., 2014). Currently,
mouse models specifically lacking the A-band region of titin are
lacking. However, a recent study has shown that the A-band of
titin is not required for thick filament assembly in zebrafish
(Myhre et al., 2014). These zebrafish have a truncated TTN,
lacking the C-terminal, A-band-associated rod domain. The ze-
brafish form normal muscle with grossly normal thick and thin178 Cell Metabolism 21, February 3, 2015 ª2015 Elsevier Inc.filament assembly, and only after embryonic development
does the sarcomere break down, consistent with TTN having a
role in sarcomere maintenance (Myhre et al., 2014). The zebra-
fish also display reduced heartbeat and cardiac edema, consis-
tent with cardiac dysfunction.
TTN has recently been identified as a major cardiomyopathy
gene in humans (Herman et al., 2012). Herman et al. captured
and sequenced the 360 exons of TTN in large cohorts of more
than 300 DCM and 200 HCM subjects as well as a control group
with normal heart function. They identified a large number of
missense mutations in TTN, even in the control population, mak-
ing these variants difficult to interpret. Instead, they focused on
truncating variants that created frameshifts, stops, and splice
site alterations. Approximately 25% of DCM patients had a trun-
cating variant in TTN, while only 1% of HCM and 3% of the con-
trol population had truncating variants, making TTN mutations
the most common genetic source of DCM to date. Truncating
variants identified in the DCM cohort disproportionately
occurred in the A-band region of TTN (Herman et al., 2012). A
recent study supports that DCM-associated TTN truncating var-
iants fall into the A band of titin (Roberts et al., 2015). Further-
more, the truncating variants in the general population fall into
TTN isoforms expressed at much lower levels in the heart.
Implications for Gene-Based Therapy and Drug
Development
Gene-based correction is now possible by targeting RNA
using reduction strategies and other methods that ‘‘bypass’’
mutations, creating internally truncated proteins. For dominant
diseases, especially in MYH7, targeting the mutant allele with
RNAi is possible in a mutation-specific manner (Jiang et al.,
2013). Developing individualized treatment plans with muta-
tion-specific sequences may be cumbersome and require
unique validation methods. As an alternative, it is possible to
target more common variation, present on the mutant but not
the normal allele. In this manner, sequences could be developed
to treat larger numbers of patients and providing a more feasible
regulatory approval pathway. The degree to which the mutant
allele must be reduced can be guided by data from human
hearts, where the expression of mutant proteins is often less
than 50% (Helms et al., 2014). Genetic ‘‘bypass’’ methods are
also being developed, and thesemethodsmanipulate RNA using
antisense sequences to induce alternative splicing to avoid the
mutation. This approach, referred to as exon skipping, takes
advantage of naturally occurring splice forms or creates newly
engineered, internally truncated proteins (Veltrop and Aartsma-
Rus, 2014). As long as there is physiological evidence that
such internally truncated proteins can compensate, these ap-
proaches may be useful for some genes linked to cardiomyopa-
thy. Complete functional restoration may not be needed, as even
partial improvement may be sufficient to improve phenotype.
Given the structural data available on bMHC, it is unlikely that in-
ternal truncationmethods are suitable forMYH7 genemutations.
However, for proteins such as titin that are composed of repeti-
tive domains, internal truncations may be a viable alternative
(Freiburg et al., 2000). Newer DNA-based gene editing methods
are an active area of research, currently being tested in cell-
based models (Li et al., 2014; Xie et al., 2014). These methods
have been employed to correct muscle disease in the mdx
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in cardiomyopathy models.
The energetic and metabolic deficits in HF offer opportunities
for small-molecule-based therapy. Modulating contractility can
occur by either blunting hypercontractile states or by using pos-
itive inotropic agents to improve deficits in contractility. A recent
potential therapeutic for reduced cardiac performance is ome-
camtivmecarbil, which directly activatesMHC through enhance-
ment of contractility, and with a corresponding improvement in
cardiac output (Cleland et al., 2011; Malik et al., 2011). Identi-
fying targets that regulate the cardiomyocyte metabolic state
has also shown some promising preliminary results. Modest im-
provements in the HCM phenotype were observed in a mouse
model carrying a MYBPC3 mutation following the application
of perhexiline, a molecule that targets mitochondrial palmitoyl-
transferase-1, altering metabolic substrate usage from fatty
acid oxidation to glycolysis (Gehmlich et al., 2015). However,
more work remains to be done to evaluate the efficacy of altering
metabolic substrate usage. The differences between the mouse
and human hearts, reflected by their distinct MHC usage, will
likely mandate that these approaches be validated in larger
mammalian hearts.
Conclusions
The genetic complexity underlying cardiomyopathy is chal-
lenging the concept of ‘‘single gene disorders.’’ The number
of genes and individual mutations is greater than had been
expected, and it has only been through the availability of next-
generation sequencing that such genetic diversity has been
appreciated. While this genetic landscape is daunting in scope
and breadth, key themes have emerged. HCM, with its distinct
phenotype, is largely linked to two key thick filament proteins.
A wealth of data supports an energetically inefficient myocar-
dium in HCM. DCM, while more genetically heterogeneous
than HCM, has one major gene, TTN, which now begins to focus
the etiology of a sizable subset of disease. With improved DNA
sequencing, it is now possible to identify combinations of ge-
netic mutations that contribute to cardiomyopathy. HCM can
now be subdivided into sarcomere and nonsarcomere HCM
with clinically meaningful differences in physiology, and the
same classification will develop for DCM. A better understanding
of the molecular subtypes of cardiomyopathy will help more pre-
cisely apply existing and evolving therapies.
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